4-Amino-3'-fluor-trans-stilben | 38693-98-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 4-Amino-3'-fluor-trans-stilben
• 英文别名: (E)-4-[2-(3-fluoro-phenyl)-vinyl]-phenylamine；4-[(E)-2-(3-fluorophenyl)ethenyl]aniline
• CAS: 38693-98-0
• 化学式: C₁₄H₁₂FN
• 分子量: 213.254
• InChiKey: KEAKHFXYOLNMHI-SNAWJCMRSA-N

物化性质

• 沸点：
  360.5±21.0 °C(Predicted)
• 密度：
  1.190±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-Amino-3'-fluor-trans-stilben 以100%的产率得到N-[2-(3-fluorophenyl)ethyl]aniline
  参考文献：
  名称：

  N-acylamino benzyl ether derivatives

  摘要：

  这项发明涉及公式1的N-酰氨基芳基衍生物，其中R1、R21、R22、R23、R3、R4、R5、R6、R7、R8、R和n如本文所定义，且X为—CHRO、—OCHR—、—CH2S—、—SCH2—、—CH2CH2—、—CH═CH—或—C≡C—。该发明的化合物是选择性的单胺氧化酶B抑制剂，因此它们在治疗由单胺氧化酶B介导的疾病中具有用途，例如用于治疗阿尔茨海默病或老年性痴呆症。

  公开号：

  US20030232883A1
• 作为产物：
  描述：

  4-Nitro-3'-fluor-trans-stilben 在 palladium on activated charcoal 一水合肼 作用下， 生成 4-Amino-3'-fluor-trans-stilben
  参考文献：
  名称：

  19 F核磁共振研究芳族化合物。第二部分 间位和对位取代的氟苯以及4位取代的3'-和4'-氟代-反式对苯二甲酸酯中的19 F化学位移

  摘要：

  已经详细研究了取代基X对19 F原子核屏蔽的间位和对位-对-X-氟苯，4-X-4'-氟-反-对苯乙烯和3'-氟的屏蔽作用-4-X-反式-苯乙烯基。检查了氟芳族化合物中19 F核的取代基化学位移与反应性参数的相关性，并对塔夫脱和斯文和卢普顿将极性取代基效应分离成场/电感和共振成分进行了重新评估。

  DOI：

  10.1039/p29720001979

文献信息

• [EN] N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS<br/>[FR] DERIVES DE N-ACYLAMINOBENZENE COMME INHIBITEURS DE LA MONOAMINE OXYDASE B SELECTIFS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2003099763A1

  公开（公告）日：2003-12-04

  This invention relates to N-acylamino aryl derivatives of the general formula (I), wherein R1 is halogen, halogen-(C1-C6)-alkyl, cyano, C1-C6-alkoxy or halogen-(C1-C6)-alkoxy; R21, R22, R23 and R24 independently from each other are selected from the group consisting of hydrogen, (C1-C6)-alkyl, halogen, halogen-(C1-C6)-alkyl, hydroxy, C1-C6-alkoxy or -CHO; R3 is hydrogen or C1-C3-alkyl; R4, R5 independently from each other are selected from the group consisting of hydrogen, C1-C6-alkyl, C1-C6-alkoxy or -COO(C1-C6)alkyl; or R4 and R5 form together with the C-atom to which they are attach a C3-C7-cycloalkyl ring; R6 is -CO-NR7R8; -COO(C1-C6)-alkyl, -CN, -NR2 or -NHC(O)R; R7 and R8 independently from each other are selected from the group consisting of hydrogen, C1-C6-alkyl, NH2 or hydroxy; R is hydrogen or C1-C6-alkyl; n is 0, 1, 2 or 3. X is -CHRO, -OCHR, -CH2S-, -SCH2-, -CH2CH2-, -CH=CH- or -C≡C-; and to pharmaceutically active acid addition salts thereof. It has been found that the compounds of general formula (I) are selective monoamine oxidase B inhibitors and they are therefore useful in the treatment of diseases mediated by monoamine oxidase B inhibitors, for example for the treatment of Alzheimer’s disease or senile dementia.

  这项发明涉及一般式(I)的N-酰氨基芳基衍生物，其中R1是卤素，卤代-(C1-C6)-烷基，氰基，C1-C6-烷氧基或卤代-(C1-C6)-烷氧基；R21、R22、R23和R24彼此独立地选自氢，(C1-C6)-烷基，卤素，卤代-(C1-C6)-烷基，羟基，C1-C6-烷氧基或-CHO的群；R3是氢或C1-C3-烷基；R4、R5彼此独立地选自氢，C1-C6-烷基，C1-C6-烷氧基或-COO(C1-C6)烷基的群；或R4和R5与它们连接的C原子一起形成一个C3-C7-环烷基环；R6是-CO-NR7R8；-COO(C1-C6)-烷基，-CN，-NR2或-NHC(O)R；R7和R8彼此独立地选自氢，C1-C6-烷基，NH2或羟基；R是氢或C1-C6-烷基；n为0、1、2或3。X是-CHRO，-OCHR，-CH2S-，-SCH2-，-CH2CH2-，-CH=CH-或-C≡C-；以及其药用活性酸盐。已发现一般式(I)的化合物是选择性单胺氧化酶B抑制剂，因此它们在治疗由单胺氧化酶B抑制剂介导的疾病中很有用，例如用于治疗阿尔茨海默病或老年性痴呆症。
• [EN] PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS<br/>[FR] DERIVES DE PYRROLIDONE TELS QUE DES INHIBITEURS MAOB
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004026825A1

  公开（公告）日：2004-04-01

  Racemic or enantiomerically pure 4-pyrrolidino derivatives of the formula (I), processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of a disease which is mediated by a monoamine oxidase B inhibitor, in particular Alzheimer's disease and senile dementia.

  光学异构体或对映纯的式(I)的4-吡咯啉衍生物，其制备方法，包含该衍生物的药物组合物，以及其在通过单胺氧化酶B抑制剂介导的疾病的预防和治疗中的用途，特别是阿尔茨海默病和老年性痴呆症。
• 4-pyrrolidino-phenyl-benzyl ether derivatives
  申请人：Iding Hans

  公开号：US20060122235A1

  公开（公告）日：2006-06-08

  The invention relates to racemic or enantiomerically pure 4-pyrrolidino derivatives, processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of illness, in particular which is mediated by monoamine oxidase B inhibitors, in particular Alzheimer's disease or senile dementia.

  本发明涉及外消旋或对映纯的4-吡咯烷基衍生物，其制备方法，包含该衍生物的制药组合物，以及其在预防和治疗疾病中的应用，特别是在通过单胺氧化酶B抑制剂介导的疾病中，特别是阿尔茨海默病或老年性痴呆症的应用。
• 4-Pyrrolidino-phenyl-benzyl ether derivatives
  申请人：——

  公开号：US20040106650A1

  公开（公告）日：2004-06-03

  The invention relates to racemic or enantiomerically pure 4-pyrrolidino derivatives, processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of illness, in particular which is mediated by monoamine oxidase B inhibitors, in particular Alzheimer's disease or senile dementia.

  本发明涉及外消旋或对映纯的4-吡咯烷基衍生物，其制备方法，包含该衍生物的制药组合物，以及它们在预防和治疗疾病方面的应用，特别是通过单胺氧化酶B抑制剂介导的疾病，特别是阿尔茨海默病或老年性痴呆症。
• Inhibition of monoamine oxidase by (E)-styrylisatin analogues
  作者：Elizna M. Van der Walt、Erika M. Milczek、Sarel F. Malan、Dale E. Edmondson、Neal Castagnoli、Jacobus J. Bergh、Jacobus P. Petzer

  DOI：10.1016/j.bmcl.2009.03.030

  日期：2009.5

  Previous studies have shown that (E)-8-(3-chlorostyryl) caffeine (CSC) is a specific reversible inhibitor of human monoamine oxidase B (MAO-B) and does not bind to human MAO-A. Since the small molecule isatin is a natural reversible inhibitor of both MAO-B and MAO-A, (E)-5-styrylisatin and (E)-6-styrylisatin analogues were synthesized in an attempt to identify inhibitors with enhanced potencies and specificities for MAO-B. The (E)-styrylisatin analogues were found to exhibit higher binding affinities than isatin with the MAO preparations tested. The (E)-5-styrylisatin analogues bound more tightly than the (E)-6 analogue although the latter exhibits the highest MAO-B selectivity. Molecular docking studies with MAO-B indicate that the increased binding affinity exhibited by the (E)-styrylisatin analogues, in comparison to isatin, is best explained by the ability of the styrylisatins to bridge both the entrance cavity and the substrate cavity of the enzyme. Experimental support for this model is shown by the weaker binding of the analogues to the Ile199Ala mutant of human MAO-B. The lower selectivity of the (E)-styrylisatin analogues between MAO-A and MAO-B, in contrast to CSC, is best explained by the differing relative geometries of the aromatic rings for these two classes of inhibitors. (C) 2009 Elsevier Ltd. All rights reserved.